FDA Clears New Interventional X-Ray Platform from United Imaging
Employing intelligent robotics and enhanced low-dose image quality, the uAngio AVIVA X-ray system also offers hands-free image review and movement.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the uAngio AVIVA interventional radiology X-ray system, which is reportedly the first interventional platform to offer a voice-assist component.
The intelligent voice assist enables hands-free image review and movement for interventional radiologists, according to United Imaging, the manufacturer of uAngio AVIVA.
The newly FDA-cleared uAngio AVIVA interventional radiology system is reportedly the first to offer intelligent voice assist to enable hands-free image review and movement, according to United Imaging, the manufacturer of uAngio AVIVA. (Image courtesy of United Imaging.)
United Imaging said other key attributes of the uAngio AVIVA platform include easy tableside access and flexibility with the 8-axis ceiling-mounted robotic system as well as proprietary artificial intelligence (AI) algorithms that facilitate quality low-dose imaging for a variety of interventional procedures.
“It is exciting to continue bringing industry firsts to healthcare. And, as with all the technology we offer, we are bringing it to market with All-In Configurations, Software Upgrades for Life™, and the other groundbreaking business models we've invented to make it simpler and more cost transparent for healthcare providers to purchase,” noted Jeffrey M. Bundy, Ph.D., the CEO of United Imaging Healthcare North America.
Possible Real-Time Adaptive Approach to Breast MRI Suggests ‘New Era’ of AI-Directed MRI
June 3rd 2025Assessing the simulated use of AI-generated suspicion scores for determining whether one should continue with full MRI or shift to an abbreviated MRI, the authors of a new study noted comparable sensitivity, specificity, and positive predictive value for biopsies between the MRI approaches.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
